C vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Citigroup presents a stark contradiction between market momentum and fundamental health. While the current price of $126.28 is well-supported by the Graham Number ($131.63), the Piotroski F-Score of 2/9 indicates severe fundamental weakness and deteriorating financial health. Despite a massive 1-year price surge of 104.9%, the company is facing negative earnings growth (-10.8% YoY) and bearish insider sentiment, including sales by the CFO. The stock is currently trading at a significant premium to its growth-based intrinsic value ($49.0), suggesting the market is pricing in a recovery that is not yet reflected in the data.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
C vs JPM: Head-to-Head Comparison
This page compares Citigroup Inc. (C) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.